PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Novartis (Taiwan) Co., Ltd Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk of Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), or Post-essential Thrombocythemia Myelofibrosis (PET-MF) 2018-09-18
Novartis (Taiwan) Co., Ltd A non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment pattern of Secukinumab and current standard of care in patient with chronic plaque psoriasis eligible for systemic treatment in the Asia-Pacific and Middle East regions (REALIA) 2018-09-18
Bayer Taiwan Co., Ltd. EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension 2018-09-18
Bayer Taiwan Co., Ltd. OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the
influence of timing to initiate sorafenib
Bayer Taiwan Co., Ltd. RIFTOS - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors 2017-01-26
Bayer Taiwan Co., Ltd. Xarelto Evidence in Real Life of Patients Preference and Satisfaction Study (X-PRESS) 2017-01-26
Johnson & Johnson Pte Ltd A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia 2017-01-26
Astellas Pharma Taiwan, Inc. An open-label, randomized, parallel study to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms including overactive bladder symptoms 2017-01-26
Pfizer Inc. An Observational Study of Xeljanz® (tofacitinib citrate) and Biologic Rheumatoid Arthritis Treatments to Characterize their General Treatment Patterns, Effectiveness and Safety in a Real-World Taiwanese Population 2017-01-26
   1 2 3 4 5